Letter from Malaysia
- PMID: 33843115
- DOI: 10.1111/resp.14057
Letter from Malaysia
Keywords: COVID-19; Malaysia; SARS-CoV-2.
Comment on
-
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2. N Engl J Med. 2021. PMID: 33264556 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Sim BL, Chidambaram SK, Wong XC, Pathmanathan MD, Peariasamy KM, Hor CP, et al. Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: a nationwide observational study. Lancet Reg Health West Pac. 2020;4:100055. https://doi.org/10.1016/j.lanwpc.2020.100055.
-
- WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19-interim WHO SOLIDARITY trial results. N Engl J Med. 2021;384:497-511.
-
- WHO. COVID-19 in Malaysia Situation Report 20. 2020. https://www.who.int/malaysia/internal-publications-detail/covid-19-in-ma.... Accessed 24 Mar 2021.
-
- Rao M, Rashid FA, Sabri FS, Jamil NN, Zain R, Hashim R, et al. Comparing nasopharyngeal swab and early morning saliva for the identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;ciaa1156. https://doi.org/10.1093/cid/ciaa1156.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
